FDA Clearance Didn't Save Pear Therapeutics From Bankruptcy
Pear Therapeutics had FDA clearance, clinical trials and tens of millions spent on reimbursement — and still went bankrupt in 2023. Here's why institutional markets break the Silicon Valley playbook.
By Amara Osei
4 min read

What's News
- Pear Therapeutics received FDA De Novo clearance for reSET in 2017 and filed for Chapter 11 in 2023.
- Pear spent tens of millions of dollars pursuing reimbursement from commercial health plans and state Medicaid programs.
- More than half of Treehub's latest founder cohort were physicians.
- Institutional sales cycles can stretch for months or years before revenue materializes.
Pear Therapeutics secured a historic FDA De Novo clearance in 2017 for reSET, its digital therapeutic for substance use disorder — and still filed for Chapter 11 bankruptcy in 2023, with its assets auctioned off. The case, cited in a new analysis of institutional-market startups, shows that regulatory success can collide head-on with commercial barriers.
The piece, published as an Entrepreneur contributor opinion column, argues that the decades-old Silicon Valley playbook — move fast, find product-market fit, scale — breaks down when a startup sells into regulated industries or large institutions such as healthcare, finance, education and government. In those markets, sales cycles, approvals and purchasing processes slow everything down.
Why the standard startup playbook fails
Venture capital has historically favored software for a structural reason: once the product works, serving additional customers requires relatively little incremental investment. Companies can test features, respond to feedback and expand without rebuilding the business at each stage.
Institutional markets don't work that way. Sales cycles can stretch for months or even years. Products may require regulatory approval, third-party validation, security reviews or integration with existing systems before a customer can use them. Even when an organization recognizes a problem, the author notes, the person experiencing it may not control the purchasing decision.
That leaves founders with a different set of questions:
- What must we prove before customers will trust this product?
- Who controls the budget?
- What existing processes will the product need to fit into?
- How long will it realistically take to turn interest into revenue?
What does the Pear Therapeutics collapse actually show?
Companies selling into institutional markets face two separate gates: proving the product works, and convincing customers to adopt it. Clearing one doesn't guarantee success at the other.
Pear is the cautionary tale. Its flagship product, reSET, received FDA De Novo clearance in 2017, supported by published randomized controlled trials demonstrating clinical efficacy. Yet the company struggled to secure consistent insurance coverage. It spent tens of millions of dollars educating commercial health plans and state Medicaid programs and pursuing dedicated coding and payment pathways. Despite FDA authorization, adoption remained slow and sales cycles stalled. The company went bankrupt in 2023.
The pattern generalizes, the author writes. A diagnostic startup might develop a test, secure FDA clearance and demonstrate the technology performs as intended — then spend months chasing a billing code, establishing reimbursement and convincing health systems to fold the product into existing workflows. The technology works; the business hasn't figured out how to get paid.
Where investors misread traction
Early customer interest is often mistaken for evidence of scalable demand, particularly when a founder lands a first customer through a pilot. A hospital pilot gives a startup a recognizable name and demonstrates interest, but it doesn't ensure a purchase, wider adoption or recommendations to other health systems.
The author lays out what founders and hospitals need to align on before a pilot counts as progress:
- A shared definition of success, with an honest answer on whether the startup can sustain itself if results take years to evaluate.
- Whether the pilot is funded, and from which budget — moving from innovation funding to operating funding often requires approval from another team or committee.
- Whether the pilot integrates with hospital workflows, since broader adoption depends on it and it's a frequently overlooked hurdle.
- Revenue potential, which is often more compelling than cost savings alone.
Without clear answers, a pilot risks becoming a costly experiment rather than a path to revenue. End-user acceptance alone doesn't establish scalable demand, and investors can be misled.
What Treehub sees in early-stage founders
The author writes from inside Treehub, which works with founders at the earliest stage of company formation, when the opportunity is promising but the company is still taking shape. Decisions about product development, partnerships and commercialization can shape a company's trajectory for years.
Treehub's approach: involve potential customers early, identify purchasing decision-makers and understand adoption barriers before investing heavily in development. More than half the founders in the firm's latest cohort were physicians, bringing direct insight into the problems they aim to solve and the realities of the healthcare system.
New tools are also opening side doors. AI can streamline administrative work and data analysis, while direct-to-consumer platforms and connected devices can help companies reach customers and validate demand before pursuing traditional institutional channels. These routes don't eliminate regulatory requirements, the author cautions, but they can create alternative paths to market.
The traditional playbook retains value — test assumptions early, build efficiently, listen to customers — but it needs adapting to the market being entered. The sharpest warning cuts both ways: moving quickly without understanding regulatory requirements creates costly setbacks, and for investors, the lesson is not to confuse early validation with commercial viability. The most successful founders in complex markets, the piece concludes, won't necessarily be the fastest — they'll be the ones who know what needs to be true before scaling makes sense.
Source: Entrepreneur
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,503 articles